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Sir,
We thank Bhandari et al (2011) for their valuable comments
on our paper (Nieuwenhuis et al, 2011). In this study, we evaluated
the effectiveness of treatment in 78 patients, known at the Dutch
Polyposis Registry, with desmoids diagnosed between 1978 and
2010. The results indicated that for intra-abdominal desmoid
tumours, both a conservative approach and surgery led to
comparable outcomes, and that also the effect of various
pharmacological therapies was similar.
The first question of Bhandari et al (2011) addressed the
indications of surgery, whether a stepwise approach was used and
whether the patients received medical treatment before surgery.
The indications for surgery were severe clinical symptoms or the
large size of the desmoid tumour. Owing to the retrospective
nature of the study, it is possible that the indications for the
surgery group and the medical treatment group may slightly differ.
However, characteristics of both groups (sex, age at diagnosis, and
median size of the desmoids) were similar. The stepwise approach,
that is, starting with medical treatment followed by surgery in case
of no response, was not used in most cases as this approach was
only recently recommended (Sturt and Clark, 2006; Vasen et al,
2008) and our study included patients that were diagnosed over a
period of 420 years. Another reason was that a considerable
proportion of patients were treated in local hospitals, making
standardised treatment less likely. None of the patients who
underwent surgery had previous history of medical treatment.
Patients who had received medical therapy before surgery were
classified in the ‘non-surgery’ group.
Another question was which type of surgery was performed.
In all cases, the intention was to remove the mesentery desmoid
tumour. If this was impossible, then only a bypass was carried out
in case of obstruction. Unfortunately, in none of the patients it was
possible to remove all desmoid tumour tissue.
The final question was about the definition of a progression-free
survival (PFS). In our study, PFS was defined as the period
between the start of medical treatment or the time of surgery and
the beginning of clinical symptoms attributed to growth of the
desmoid. We realise that this is not a standardised method for
measuring tumour progression. However, we think that the
presence of new complaints because of tumour growth is a
clinically important parameter. In many cases, tumour growth was
confirmed by MRI or by CT scanning. However, we agree with
Bhandari et al (2011) that in familial adenomatous polyposis
patients, it is sometimes difficult to attribute abdominal com-
plaints to the desmoid tumour, because most patients had also
colorectal surgery and some of them may have complaints
associated with adhesions.
We very much appreciate the critical notes of Bhandari et al
(2011) and fully realise that most questions can only be completely
addressed by performing a prospective study.
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